WAVEMAN · COMPANY

NAGE · Niagen Bioscience, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

NAGE

Name: Niagen Bioscience, Inc. (NAGE) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Niagen Bioscience, Inc.

PHARMA & BIOTECH · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · CIK 0001386570

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+29.9%

XBRL, annual

NET MARGIN

13.4%

CONVERSIONS · 180D

codes C/M, not in net · $52.2K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

66 funds added or opened last quarter

more than 51% of Pharma & Biotech

REVENUE

+29.9% year over year

more than 74% of Pharma & Biotech

MARGIN

13.4% net margin

more than 84% of Pharma & Biotech

BUYBACKS

$5.1M repurchased, FY to 2026-06-30

below 77% of Pharma & Biotech

SHORT

5.7% of shares outstanding short · 7.2 days to cover · settled 2026-07-31

more than 59% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

66 funds added or opened positions in the latest 13F quarter, of 141 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -67.9%

-67.9%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 66 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Niagen Bioscience, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Pamir Ozan

Chief Financial Officer

BUY

2025-11-14

4,464.96

$30.4K

Pamir Ozan

Chief Financial Officer

BUY

2025-11-14

2,220.44

$15.2K

2 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

4,184,659.0 sh

$13.3M

SteelPeak Wealth, LLC

3,500,129.0 sh

$11.2M

VANGUARD CAPITAL MANAGEMENT LLC

2,147,018.0 sh

$6.8M

Qube Research & Technologies Ltd

1,625,016.0 sh

$5.2M

GEODE CAPITAL MANAGEMENT, LLC

1,478,603.0 sh

$4.7M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

ACUITAS US MICROCAP FUND

$560.1K POSITION · AS OF 2026-03-31

0.6%

Gabelli Love Our Planet & People ETF

$58.1K POSITION · AS OF 2026-03-31

0.4%

Invesco NASDAQ Future Gen 200 ETF

$49.3K POSITION · AS OF 2026-02-28

0.4%

Columbia Integrated Small Cap Growth Fund

$86.0K POSITION · AS OF 2026-02-28

0.3%

SIIT SMALL CAP FUND

$349.6K POSITION · AS OF 2026-02-28

0.2%

Gabelli SRI Fund, Inc.

$37.5K POSITION · AS OF 2026-03-31

0.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · Robert Fried

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$8.4M

$10.3M

$637.2K

+32%

+48%

2024

$1.2M

$3.0M

$408.7K

+11%

+17%

2023

$1.2M

$1.0M

$691.6K

-70%

+13%

2022

$1.2M

$843.4K

$721.4K

-65%

+13%

2021

$1.1M

$2.1M

$786.3K

-22%

+11%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$129.4M	$99.6M	$83.6M	$72.0M
GROSS PROFIT	$83.2M	$61.6M	$50.8M	$42.8M
OPERATING INCOME	$16.3M	$7.7M	$-5.6M	$-18.6M
NET INCOME	$17.4M	$8.6M	$-4.9M	$-16.5M
EPS (DILUTED)	0.20	0.11	-0.07	-0.24
OPERATING CASH FLOW	$13.5M	$12.1M	$7.1M	$-15.1M
CASH	—	$44.5M	$27.2M	$20.3M
BUYBACKS	$251.0K	$0	—	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE